<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237129</url>
  </required_header>
  <id_info>
    <org_study_id>GL-ASP-1008</org_study_id>
    <nct_id>NCT04237129</nct_id>
  </id_info>
  <brief_title>PK/PD Study of Gan &amp; Lee Insulin Aspart Injection vs. US &amp; EU NovoLog®/NovoRapid® in Healthy Males</brief_title>
  <official_title>A Glucose Clamp Trial Investigating The Biosimilarity of Gan &amp; Lee Insulin Aspart Injection (Insulin Aspart 100 U/ml) With US and EU Insulin Aspart Comparator Products (NovoLog®/NovoRapid®) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gan and Lee Pharmaceuticals, USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gan and Lee Pharmaceuticals, USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      To demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of Gan &amp; Lee Insulin
      Aspart Injection with both EU-approved NovoRapid® and US-licensed NovoLog® (Reference
      Products) in healthy male subjects

      Secondary objectives:

      To compare the PK and PD parameters of the three insulin aspart preparations

      To evaluate the single dose safety and local tolerability of the three insulin aspart
      preparations
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Actual">December 16, 2019</completion_date>
  <primary_completion_date type="Actual">December 16, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCins.0-12h</measure>
    <time_frame>0 -12 hours</time_frame>
    <description>PK endpoint: The area under the insulin concentration curve from 0 to 12 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cins.max</measure>
    <time_frame>0 -12 hours</time_frame>
    <description>PK endpoint: The maximum observed insulin concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCGIR.0-12h</measure>
    <time_frame>0 - 12 hours</time_frame>
    <description>PD endpoint: The area under the glucose infusion rate curve from 0 to 12 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GIRmax</measure>
    <time_frame>0 - 12 hours</time_frame>
    <description>PD endpoint: The maximum glucose infusion rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCins.0-2h</measure>
    <time_frame>0 - 2 hours</time_frame>
    <description>PK endpoint: The area under the insulin concentration curve from 0 to 2 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCins.0-∞</measure>
    <time_frame>0 - 12 hours</time_frame>
    <description>PK endpoint: The area under the insulin concentration-time curve from 0 hours to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tins.max</measure>
    <time_frame>Up to Day 68</time_frame>
    <description>PK endpoint: The time to maximum observed insulin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t50%-ins(early)</measure>
    <time_frame>Up to Day 68</time_frame>
    <description>PK endpoint: The time to half-maximum insulin concentration before Cins.max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t50%-ins(late)</measure>
    <time_frame>Up to Day 68</time_frame>
    <description>PK endpoint: The time to half-maximum insulin concentration after Cins.max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½</measure>
    <time_frame>Up to Day 68</time_frame>
    <description>PK endpoint: The terminal serum elimination half-life calculated as t½=ln2/λz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>Up to Day 68</time_frame>
    <description>PK endpoint: The terminal elimination rate constant of insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCGIR.0-2h</measure>
    <time_frame>0 - 2 hours</time_frame>
    <description>PD endpoint: The area under the glucose infusion rate curve from 0 to 2 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tGIR.max</measure>
    <time_frame>Up to Day 68</time_frame>
    <description>PD endpoint: The time to maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tGIR.50%-early</measure>
    <time_frame>Up to Day 68</time_frame>
    <description>PD endpoint: The time to half-maximum glucose infusion rate before GIRmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tGIR.50%-late</measure>
    <time_frame>Up to Day 68</time_frame>
    <description>PD endpoint: The time to half-maximum glucose infusion rate after GIRmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD endpoint</measure>
    <time_frame>Up to Day 68</time_frame>
    <description>time to onset of action</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and local tolerability</measure>
    <time_frame>Up to Day 68</time_frame>
    <description>Number of participants experiencing treatment-emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Gan &amp; Lee Insulin Aspart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 units/mL, 3 ml prefilled pen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NovoRapid® Insulin Aspart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Product approved and marketed in the EU
FlexPen100 units/mL prefilled pen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NovoLog® Insulin Aspart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Product approved and marketed in the US
FlexPen100 units/mL prefilled pen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gan &amp; Lee Insulin Aspart</intervention_name>
    <description>All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area.</description>
    <arm_group_label>Gan &amp; Lee Insulin Aspart</arm_group_label>
    <arm_group_label>NovoLog® Insulin Aspart</arm_group_label>
    <arm_group_label>NovoRapid® Insulin Aspart</arm_group_label>
    <other_name>NovoRapid® EU</other_name>
    <other_name>NovoLog® US</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent obtained before any trial-related activities.
             Trial-related activities are any procedures that would not have been done during
             normal management of the subject

          2. Healthy male subjects

          3. Age between 18 and 64 years, both inclusive

          4. Body Mass Index (BMI) between 18.5 and 29.0 kg/m^2, both inclusive

          5. Fasting plasma glucose concentration &lt;= 5.50 mmol/L (100 mg/dL) at screening

          6. Considered generally healthy upon completion of medical history, physical examination,
             vital signs, ECG and analysis of laboratory safety variables, as judged by the
             Investigator

        Exclusion Criteria:

          1. Known or suspected hypersensitivity to investigational medicinal products (IMPs) or
             related product

          2. Previous participation in this trial. Participation is defined as randomized

          3. Use of other investigational drugs within five half-lives for enrolment or receipt of
             any medicinal product in clinical development within 30 days before randomization in
             this trial, whichever is longer

          4. History of multiple and/or severe allergies to drugs or foods or a history of severe
             anaphylactic reaction.

          5. Clinically significant abnormal values for haematology, biochemistry, coagulation, or
             urinalysis as judged by the Investigator

          6. Increased risk of thrombosis, e.g subjects with a history of deep leg vein thrombosis
             or family history of deep leg vein thrombosis, as judged by the Investigator

          7. A positive result in the alcohol and/or urine drug screen at the screening visit

          8. Positive to the screening test for Hepatitis Bs antigen or Hepatitis C antibodies
             and/or a positive result to the test for HIV-1/2 antibodies or HIV-1 antigen

          9. Blood donation or blood loss of m ore than 500 mL within the last 3 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew E Barton, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gan &amp; Lee Pharmaceuticals USA Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Mainz GmbH &amp; Co. KG</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatinate</state>
        <zip>D-55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Insulin</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Basal</keyword>
  <keyword>Bolus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

